YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Company Logo PDX adoption is rising as pharma seeks predictive oncology models for precision medicine, biomarker discovery and drug screening, supported by sequencing advances and research partnerships. Dublin, Sept. 22, 2026 (GLOBE NEWSWI…
Shares of Champions Oncology, Inc. CSBR have lost 1.8% since the company reported its earnings for the quarter ended July 31, 2026. This compares with the S&P 500 Index's 0.2% rise over the same time frame. Over the past month, the stock h…
Earnings Call Insights: Champions Oncology (CSBR) Q1 fiscal 2027 MANAGEMENT VIEW * "When we spoke in July, I said fiscal '26 was an investment year and that the onus was on us to deliver in fiscal 2027. The first quarter is a strong data p…
Key Points Interested in Champions Oncology, Inc.? Here are five stocks we like better. Revenue and profitability improved: First-quarter fiscal 2027 revenue rose 9% to $15.2 million, while adjusted EBITDA increased to $671,000 from $59,00…
Shares of Champions Oncology, Inc. CSBR have lost 10.9% since the company reported its earnings for the quarter ended April 30, 2026. This compares to the S&P 500 Index's 0.9% decline over the same time frame. Over the past month, the stoc…
Earnings Call Insights: Champions Oncology (CSBR) Q4 fiscal 2026 MANAGEMENT VIEW * CEO Robert Brainin said the company delivered “record annual revenue” and “met our commitment to full year positive adjusted EBITDA,” including “positive ad…
Image source: The Motley Fool. DATE Thursday, March 12, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer — Robert BraininChief Financial Officer — David Miller TAKEAWAYS Total Revenue -- $16.6 million, a decrease of approxima…
Champions Oncology, Inc. Q3 2026 Earnings Call Summary - Moby Strategic Performance and Operational Context Record services revenue was driven by strong conversion of previously booked work and the completion of backlog from prior quarters…
On February 17, 2026, Battery Management Corp. disclosed an increase of 839,864 shares in Braze(NASDAQ:BRZE), an estimated $24.88 million trade based on quarterly average pricing. What happened According to a February 17, 2026, SEC filing,…
As of December 31, 2025, Battery Management Corp. disclosed in a U.S. Securities and Exchange Commission filing that it sold out its entire Zeta Global Holdings Corp.(NYSE:ZETA) stake, an estimated $9.05 million transaction. What happened…
On February 17, 2026, Battery Management Corp. disclosed a new position, acquiring 11,356,669 shares in Kodiak AI(NASDAQ:KDK) for an estimated $124.01 million. What happened According to a SEC filing dated February 17, 2026, Battery Manage…
On February 17, 2026, Battery Management disclosed in a U.S. Securities and Exchange Commission (SEC) filing that it sold 374,479 shares of Sprinklr(NYSE:CXM), an estimated $2.85 million trade based on quarterly average pricing. What happe…
Image source: The Motley Fool. Date Monday, September 15, 2025 at 4:30 p.m. ET Call participants Chief Executive Officer — Robert Brainin Chief Financial Officer — David Miller Need a quote from a Motley Fool analyst? Email pr@fool.com Ful…
Image source: The Motley Fool. DATE Wednesday, September 11, 2024 at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer — Ronnie Morris Chief Financial Officer — David Miller Need a quote from a Motley Fool analyst? Email pr@fool.com F…
Image source: The Motley Fool. Date Wednesday, December 11, 2024 at 4:30 p.m. ET Call participants Chief Executive Officer — Ronnie Morris Chief Financial Officer — David Miller Need a quote from a Motley Fool analyst? Email pr@fool.com Fu…
Image source: The Motley Fool. DATE Tuesday, March 11, 2025 at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer — Ronnie Morris Chief Financial Officer — David Miller Need a quote from a Motley Fool analyst? Email pr@fool.com Full Co…
Image source: The Motley Fool. Date Monday, December 15, 2025 at 4:30 p.m. ET Call participants Chief Executive Officer — Robert Brainin Chief Financial Officer — David Miller Need a quote from a Motley Fool analyst? Email pr@fool.com Full…
Image source: The Motley Fool. DATE Wednesday, July 23, 2025 at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer — Ronnie Morris Chief Financial Officer — David Barry Miller Full Conference Call Transcript Ronnie Morris: Good afterno…
Earnings Call Insights: Champions Oncology (CSBR) Q2 2026 MANAGEMENT VIEW * CEO Robert Brainin stated the company's three core goals for the year are to deliver year-on-year revenue growth, invest in growth levers—especially the data platf…
Earnings Call Insights: Champions Oncology (CSBR) Q1 2026 MANAGEMENT VIEW * Rob Brainin, CEO, stated that "fiscal 2025 is a pivotal year for Champions as we rebounded after a difficult 2024 to achieve record annual revenue and profitabilit…
Champions Oncology Inc (NASDAQ:CSBR [https://www.chartmill.com/stock/quote/CSBR]) reported its first-quarter fiscal 2026 earnings, posting record quarterly revenue of $14.0 million but falling short of profitability expectations. The trans…
September S&P 500 E-Mini futures (ESU25) are up +0.19%, andSeptember Nasdaq 100 E-Mini futures (NQU25) are up +0.08% this morning, pointing to a slightly higher open on Wall Street amid optimism ahead of a widely expected interest rate cut…
Investing.com - Champions Oncology (NASDAQ: CSBR) reported first quarter EPS of $-0.070, $0.13 worse than the analyst estimate of $0.060. Revenue for the quarter came in at $12.36M versus the consensus estimate of $15.7M. Champions Oncolog…
HACKENSACK, NJ / ACCESSWIRE / August 1, 2023 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions, today announced an agreement to adop…
Record Annual Revenue of $53.9 Million HACKENSACK, NJ / ACCESSWIRE / July 24, 2023 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharm…
HACKENSACK, NJ / ACCESSWIRE / July 20, 2023 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report i…
HACKENSACK, NJ / ACCESSWIRE / April 17, 2023 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled research organization that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic (PPM…
HACKENSACK, NJ / ACCESSWIRE / April 5, 2023 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, today announc…
HACKENSACK, NJ / ACCESSWIRE / March 15, 2023 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, today…
HACKENSACK, NJ / ACCESSWIRE / March 13, 2023 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will…
Champions Oncology, Inc. (NASDAQ:CSBR) Q2 2023 Earnings Call Transcript December 13, 2022 Operator: Good day, ladies and gentlemen, and welcome to the Champions Oncology Second Quarter Fiscal Year 2023 Earnings Call. At this time, all part…
HACKENSACK, NJ / ACCESSWIRE / December 13, 2022 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, to…
HACKENSACK, NJ / ACCESSWIRE / December 9, 2022 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will repor…
HACKENSACK, NJ / ACCESSWIRE / September 8, 2022 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, to…
HACKENSACK, NJ / ACCESSWIRE / September 6, 2022 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, wi…
If you want to know who really controls Champions Oncology, Inc. (NASDAQ:CSBR), then you'll have to look at the makeup of its share registry. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, i…